FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064563669> ?p ?o ?g. }

• W2064563669 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCInterleukin-6 or IL-6 is a pleiotropic cytokine which is implicated in the regulation of immune response, but is also involved in regulating the growth of various malignant tumors. Mounting evidence suggests that IL-6 contributes to prostate cancer progression. Activated IL-6 has been shown to be elevated in the sera from patients with metastatic prostate cancer and it appears that the prostate tissue itself is a source of IL-6 and its receptor. Experimental data suggests that the IL-6/IL-6R signaling axis is an autocrine and paracrine growth factor in androgen independent prostate cancer cell lines and can activate a variety of signal transduction cascades, some of which may activate androgen receptor activity. In the present study we examined the role of IL6-induced Stat3 activation in the development and progression of prostate cancer and its possible role as a target for the treatment of prostate cancer using the prostate-specific conditional targeting PTEN knockout mouse model. In PTEN-mutant mice, elevated levels of IL6/IL-6R correlated with increased cellular proliferation in non-castrate and castrate prostate cancer (CRPC). Similar to human prostate cancer, mice with CPRC showed elevated levels of IL-6 and IL6-R in both serum and prostate tissue. To establish a therapeutic role for IL6/IL6R inhibition, we conducted a series of pharmacodynamic studies using an anti-mouse IL-6R antibody (MR-16) in tumor bearing homozygous PTEN-mutant mice. Our data shows that STAT3 activation was inhibited in a dose dependent manner during acute IL6-R blockade. Inhibition of STAT3 activity after chronic IL-6R blockade was transient. However, at day 45 of treatment, tumor cell proliferation was inhibited and apoptosis was induced. These findings show that this mouse model is relevant for the study of Stat3 signaling and tumor progression and inhibition of Stat3 transcriptional activation by upstream signal blockade may be a promising approach for molecularly targeted therapeutic strategies in human prostate cancer. Thus this study will serve as the foundation for future drug intervention studies designed to assess the efficacy of targeting the JAK/STAT signal pathway using targeted monotherapy and combination drug therapy models.Citation Format: Yurie Kura, Marco A. De Velasco, Yasuyuki Kobayashi, Naomi Ando, Emiko Fukushima, Yutaka Yamamoto, Yuji Hatanaka, Nobutaka Shimizu, Kazuhiro Yoshimura, Masahiro Nozawa, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura. Interleukin-6 (IL-6) as a therapeutic target in prostate cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1226. doi:10.1158/1538-7445.AM2013-1226" @default.
• W2064563669 created "2016-06-24" @default.
• W2064563669 creator A5004282323 @default.
• W2064563669 creator A5044704087 @default.
• W2064563669 creator A5047104997 @default.
• W2064563669 creator A5047840224 @default.
• W2064563669 creator A5051123041 @default.
• W2064563669 creator A5057857434 @default.
• W2064563669 creator A5058934672 @default.
• W2064563669 creator A5059877323 @default.
• W2064563669 creator A5060375630 @default.
• W2064563669 creator A5061277451 @default.
• W2064563669 creator A5061542577 @default.
• W2064563669 creator A5070107777 @default.
• W2064563669 creator A5083740330 @default.
• W2064563669 date "2013-04-15" @default.
• W2064563669 modified "2023-09-26" @default.
• W2064563669 title "Abstract 1226: Interleukin-6 (IL-6) as a therapeutic target in prostate cancer." @default.
• W2064563669 doi "https://doi.org/10.1158/1538-7445.am2013-1226" @default.
• W2064563669 hasPublicationYear "2013" @default.
• W2064563669 type Work @default.
• W2064563669 sameAs 2064563669 @default.
• W2064563669 citedByCount "1" @default.
• W2064563669 countsByYear W20645636692015 @default.
• W2064563669 crossrefType "proceedings-article" @default.
• W2064563669 hasAuthorship W2064563669A5004282323 @default.
• W2064563669 hasAuthorship W2064563669A5044704087 @default.
• W2064563669 hasAuthorship W2064563669A5047104997 @default.
• W2064563669 hasAuthorship W2064563669A5047840224 @default.
• W2064563669 hasAuthorship W2064563669A5051123041 @default.
• W2064563669 hasAuthorship W2064563669A5057857434 @default.
• W2064563669 hasAuthorship W2064563669A5058934672 @default.
• W2064563669 hasAuthorship W2064563669A5059877323 @default.
• W2064563669 hasAuthorship W2064563669A5060375630 @default.
• W2064563669 hasAuthorship W2064563669A5061277451 @default.
• W2064563669 hasAuthorship W2064563669A5061542577 @default.
• W2064563669 hasAuthorship W2064563669A5070107777 @default.
• W2064563669 hasAuthorship W2064563669A5083740330 @default.
• W2064563669 hasConcept C121608353 @default.
• W2064563669 hasConcept C126322002 @default.
• W2064563669 hasConcept C128240485 @default.
• W2064563669 hasConcept C170493617 @default.
• W2064563669 hasConcept C2776235491 @default.
• W2064563669 hasConcept C2777609662 @default.
• W2064563669 hasConcept C2778690821 @default.
• W2064563669 hasConcept C2780192828 @default.
• W2064563669 hasConcept C502942594 @default.
• W2064563669 hasConcept C55493867 @default.
• W2064563669 hasConcept C61367390 @default.
• W2064563669 hasConcept C62478195 @default.
• W2064563669 hasConcept C71924100 @default.
• W2064563669 hasConcept C7876069 @default.
• W2064563669 hasConcept C86554907 @default.
• W2064563669 hasConcept C86803240 @default.
• W2064563669 hasConceptScore W2064563669C121608353 @default.
• W2064563669 hasConceptScore W2064563669C126322002 @default.
• W2064563669 hasConceptScore W2064563669C128240485 @default.
• W2064563669 hasConceptScore W2064563669C170493617 @default.
• W2064563669 hasConceptScore W2064563669C2776235491 @default.
• W2064563669 hasConceptScore W2064563669C2777609662 @default.
• W2064563669 hasConceptScore W2064563669C2778690821 @default.
• W2064563669 hasConceptScore W2064563669C2780192828 @default.
• W2064563669 hasConceptScore W2064563669C502942594 @default.
• W2064563669 hasConceptScore W2064563669C55493867 @default.
• W2064563669 hasConceptScore W2064563669C61367390 @default.
• W2064563669 hasConceptScore W2064563669C62478195 @default.
• W2064563669 hasConceptScore W2064563669C71924100 @default.
• W2064563669 hasConceptScore W2064563669C7876069 @default.
• W2064563669 hasConceptScore W2064563669C86554907 @default.
• W2064563669 hasConceptScore W2064563669C86803240 @default.
• W2064563669 hasLocation W20645636691 @default.
• W2064563669 hasOpenAccess W2064563669 @default.
• W2064563669 hasPrimaryLocation W20645636691 @default.
• W2064563669 hasRelatedWork W1967822656 @default.
• W2064563669 hasRelatedWork W1993571844 @default.
• W2064563669 hasRelatedWork W2028739425 @default.
• W2064563669 hasRelatedWork W2048785398 @default.
• W2064563669 hasRelatedWork W2051635101 @default.
• W2064563669 hasRelatedWork W2062292078 @default.
• W2064563669 hasRelatedWork W2068636161 @default.
• W2064563669 hasRelatedWork W2080436420 @default.
• W2064563669 hasRelatedWork W2253971826 @default.
• W2064563669 hasRelatedWork W2313161041 @default.
• W2064563669 hasRelatedWork W2329142505 @default.
• W2064563669 hasRelatedWork W2331035590 @default.
• W2064563669 hasRelatedWork W2483580077 @default.
• W2064563669 hasRelatedWork W2485932207 @default.
• W2064563669 hasRelatedWork W2775028758 @default.
• W2064563669 hasRelatedWork W2887662682 @default.
• W2064563669 hasRelatedWork W2896285889 @default.
• W2064563669 hasRelatedWork W3182546455 @default.
• W2064563669 hasRelatedWork W3199237048 @default.
• W2064563669 hasRelatedWork W1533680988 @default.
• W2064563669 isParatext "false" @default.
• W2064563669 isRetracted "false" @default.
• W2064563669 magId "2064563669" @default.
• W2064563669 workType "article" @default.